Wedbush lowered shares of Arbutus Biopharma (NASDAQ:ABUS) from an outperform rating to a neutral rating in a research report sent to investors on Monday, Marketbeat.com reports. They currently have $6.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $9.00. Wedbush also issued estimates for Arbutus Biopharma’s Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($1.31) EPS, FY2020 earnings at ($1.28) EPS, FY2021 earnings at ($1.19) EPS and FY2022 earnings at ($0.80) EPS.

Several other analysts also recently issued reports on ABUS. Zacks Investment Research downgraded Arbutus Biopharma from a hold rating to a sell rating in a research note on Thursday, January 18th. ValuEngine downgraded Arbutus Biopharma from a sell rating to a strong sell rating in a research note on Friday, December 15th. BidaskClub upgraded Arbutus Biopharma from a sell rating to a hold rating in a research note on Saturday, February 10th. Finally, Chardan Capital restated a buy rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $12.38.

How to Become a New Pot Stock Millionaire

Arbutus Biopharma stock opened at $4.75 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.03 and a current ratio of 8.85. Arbutus Biopharma has a one year low of $2.95 and a one year high of $8.25. The company has a market capitalization of $275.35, a P/E ratio of -3.06 and a beta of 1.02.

Arbutus Biopharma (NASDAQ:ABUS) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $0.70 million. research analysts anticipate that Arbutus Biopharma will post -1.67 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC boosted its stake in Arbutus Biopharma by 98.3% in the 4th quarter. Spark Investment Management LLC now owns 23,000 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 11,400 shares during the period. Citadel Advisors LLC bought a new stake in Arbutus Biopharma in the 4th quarter valued at $146,000. Two Sigma Investments LP bought a new stake in Arbutus Biopharma in the 4th quarter valued at $215,000. Goldman Sachs Group Inc. bought a new stake in Arbutus Biopharma in the 4th quarter valued at $275,000. Finally, Vanguard Group Inc. boosted its stake in Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the period. Institutional investors and hedge funds own 62.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma (ABUS) Lowered to “Neutral” at Wedbush” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/arbutus-biopharma-abus-lowered-to-neutral-at-wedbush/1958510.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.